Meta AnalysisID 7481

二乙酰吗啡用于阿片受体激动剂治疗的有效性:基于患者报告结局的系统评价

CRD42023492183

Is opioid agonist treatment with intravenous diacetylmorphine alone or in combination with another opioid agonist treatment medication more effective in opioid-dependent individuals in improving mental or physical health

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final meta_analysis record.

Meta Analysis Id
7481
Evidence Id
16039
Core Evidence Id
16039
Source Meta Analysis Id
7474
Herb2 Meta Analysis Id
HBMA007474
Crd Id
CRD42023492183
Title
Effectiveness of diacetylmorphine for opioid agonist treatment: A systematic review of patient-reported outcomes
Review Question
Is opioid agonist treatment with intravenous diacetylmorphine alone or in combination with another opioid agonist treatment medication more effective in opioid-dependent individuals in improving mental or physical health, reducing drug use (including alcohol), improving quality of life, or social functioning compared to opioid agonist treatment with racemic methadone, levomethadone, buprenorphine, buprenorphine/naloxone, codeine, slow-release morphine, or dihydrocodeine?
Study Type Included
We will include randomized controlled trials (RCTs), non-randomized controlled trials (NRS), or observational studies (prospective or retrospective cohort studies or case-control studies). We will exclude qualitative studies, cross-sectional studies, cost-effectiveness studies, mathematical modeling studies, ecological studies, case series, and principally studies with no intervention and control group.
Condition Being Studied
Opioid use disorder/opioid dependence. Opioid agonist treatment for improving patient-reported outcomes.
Participant
Inclusion: Adults with opioid use disorder/opioid dependence from illegal opioids (as diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD)). Exclusion: Neonatals, children and adolescents (under 18 years of age), pregnant people, only veterans, indigenous people, people with illegal status or people in prison as study population, people who are addicted to (prescribed) opioids as pain-relieving medicine.
Animal
Human Disease Modelled
Intervention
Opioid agonist treatment (OAT) with intravenous diacetylmorphine alone or in combination with another OAT medication such as racemic methadone, levomethadone, buprenorphine, buprenorphine/naloxone, codeine, slow-release oral morphine or dihydrocodeine.
Comparator Control
Opioid agonist treatment (OAT) with racemic methadone, levomethadone, buprenorphine, buprenorphine/naloxone, codeine, slow-release oral morphine or dihydrocodeine.
Main Outcome
Changes in the patient-reported outcomes (PRO) mental health, physical health, drug use incl. alcohol, quality of life, treatment satisfaction, and social functioning from baseline to at least six months follow-up.
Outcome Measure
Additional Outcome
Study Method
Intervention, Systematic review
Keyword
MeSH headings have not been applied to this record
Contact
Kirsten Lehmann [email protected]
Organisational Affiliation
University Medical Center Hamburg-Eppendorf, Centre for Interdisciplinary Addiction Research https://www.zis-hamburg.de
Funding Source
Other Selection Criteria
Final Publication
Same Topic Review
Published Protocol
Review Type
Language
English
Country
Germany
Review Stage
Review Ongoing
First Submission Date
2023-12-10
Registration Date
2023-12-21
Anticipated Start Date
2023-12-17
Anticipated Completion Date
2024-09-01
Title Cn
二乙酰吗啡用于阿片受体激动剂治疗的有效性:基于患者报告结局的系统评价
Title En
Effectiveness of diacetylmorphine for opioid agonist treatment: A systematic review of patient-reported outcomes
Bilingual Status
complete